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EDITORIAL COMMENT

Drug-Coated Balloon Failure Following
Femoro-Popliteal Intervention
Where to Draw the Line?*
Yasar Sattar, MD,a Herbert D. Aronow, MD, MPH,b Mahboob Alam, MDc
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In treating lower-extremity PAD using endovascular
means, it is often said that “the enemy of good is bet-
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